Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J’s COVID Vaccine Contract With US Bucks Trend Of Increasingly Lucrative Deals

Executive Summary

Estimated $14 price per dose for Janssen’s investigational vaccine is first drop in value since Operation Warp Speed started signing contracts. The $1bn purchase order for 100 million doses and earlier $456m for development work is considerably less lucrative than the $2.1bn deal with GSK/Sanofi announced last week, especially since Janssen’s product may end up being a one-dose regimen.

You may also be interested in...



Congress Eyes Vaccine Pricing With Spotlight On Pfizer As COVID Boosters Look More Likely

Senate hearing offers early signals that US lawmakers will be closely watching how COVID-19 vaccine pricing evolves. Biden team pledges to try to make contracting more transparent.

Coronavirus Update: Lilly To Seek EUA For Olumiant

Hot on the heels of positive news from its monoclonal antibody treatment, Lilly aims to seek emergency authorization for anti-inflammatory treatment Olumiant.

J&J COVID Vaccine: Single-Dose Format Will ‘Expedite’ Phase III Trial

Effectiveness can be evaluated more quickly because researchers won’t have to wait for the second dose, company executive notes during briefing on the launch of the Phase III study.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS142682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel